PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31517438-2	2019	We observed that iron (an essential cofactor of dioxygenases including prolyl hydroxylases [PHDs]) depletion by deferoxamine blocked MCL cells" proliferation, increased expression of DNA damage marker gammaH2AX, induced cell cycle arrest and decreased cyclin D1 level.	Deferoxamine	112-124	cyclin D1	Homo sapiens	252-261	
34204881-6	2021	DFO prevented DNA damage and stress-induced senescence of hMESCs, as evidenced by reduced levels of reactive oxygen species, lipofuscin, cyclin D1, decreased SA-beta-Gal activity, and improved mitochondrial function.	Deferoxamine	0-3	cyclin D1	Homo sapiens	137-146	
16155412-6	2005	Using a transfected COS-7 cell model system, we demonstrate that the activity of a cyclin D1 promoter-luciferase construct increased under hypoxic conditions or DFO treatment.	Deferoxamine	161-164	cyclin D1	Homo sapiens	83-92	
23300831-11	2012	Treatment of desferrioxamine, a HIF-1alpha activator, led to further downregulation of expressions of cyclin D1 and c-Myc in osteoblasts.	Deferoxamine	13-28	cyclin D1	Homo sapiens	102-111	
17197429-6	2007	Iron chelation of cells in culture using desferrioxamine (DFO) or 2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone (311) decreased cyclin D1 protein levels after 14 hours and was rescued by the addition of Fe.	Deferoxamine	41-56	cyclin D1	Homo sapiens	135-144	
17197429-6	2007	Iron chelation of cells in culture using desferrioxamine (DFO) or 2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone (311) decreased cyclin D1 protein levels after 14 hours and was rescued by the addition of Fe.	Deferoxamine	58-61	cyclin D1	Homo sapiens	135-144